[1] XIE Y, ZHANG L, XIONG Q, et al. Bench-to-bedside strategies for osteoporotic fracture: From osteoimmunology to mechanosensation. Bone Res. 2019;7:25.
[2] CHEN J, HONG Z, ZHAO C, et al. Associations between polymorphisms of the PDLIM4 gene and susceptibility to osteoporotic fracture in an elderly population of Han Chinese. Biosci Rep. 2019;39(1): BSR20181505.
[3] LIU DB, SUI C, WU TT, et al. Association of Bone Morphogenetic Protein (BMP)/Smad Signaling Pathway with Fracture Healing and Osteogenic Ability in Senile Osteoporotic Fracture in Humans and Rats. Med Sci Monit. 2018;24:4363-4371.
[4] LU J, REN Z, LIU X, et al. Osteoporotic Fracture Guidelines and Medical Education Related to the Clinical Practices: A Nationwide Survey in China. Orthop Surg. 2019;11:569-577.
[5] LIU R, CHAO A, WANG K, et al. Incidence and risk factors of medical complications and direct medical costs after osteoporotic fracture among patients in China. Arch Osteoporos. 2018;13:12.
[6] KIM HY, HA YC, KIM TY, et al. Healthcare Costs of Osteoporotic Fracture in Korea: Information from the National Health Insurance Claims Database, 2008-2011. J Bone Metab. 2017;24:125-133.
[7] TAGUCHI Y, INOUE Y, KIDO T, et al. Treatment costs and cost drivers among osteoporotic fracture patients in Japan: a retrospective database analysis. Arch Osteoporos. 2018;13:45.
[8] BARTEL DP. Metazoan MicroRNAs. Cell. 2018;173:20-51.
[9] PICKERING ME, MILLET M, ROUSSEAU JC, et al. Selected serum microRNA, abdominal aortic calcification and risk of osteoporotic fracture]. PLoS One. 2019;14:e0216947.
[10] SUN X, GUO Q, WEI W, et al. Current Progress on MicroRNA-Based Gene Delivery in the Treatment of Osteoporosis and Osteoporotic Fracture. Int J Endocrinol. 2019;2019:6782653.
[11] TANG X, BAI Y, ZHANG Z, et al. A validated miRNA signature for the diagnosis of osteoporosis related fractures using SVM algorithm classification. Exp Ther Med. 2020;20:2209-2217.
[12] RAMIREZ-SALAZAR EG, CARRILLO-PATINO S, HIDALGO-BRAVO A, et al. Serum miRNAs miR-140-3p and miR-23b-3p as potential biomarkers for osteoporosis and osteoporotic fracture in postmenopausal Mexican-Mestizo women. Gene. 2018;679:19-27.
[13] FISCHER M, QUAAS M, STEINER L, et al. The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes. Nucleic Acids Res. 2016;44:164-174.
[14] FANG H, ZHANG H, WANG Z, et al. Systemic immune-inflammation index acts as a novel diagnostic biomarker for postmenopausal osteoporosis and could predict the risk of osteoporotic fracture. J Clin Lab Anal. 2020;34:e23016.
[15] BOTTANI M, BANFI G, LOMBARDI G. The Clinical Potential of Circulating miRNAs as Biomarkers: Present and Future Applications for Diagnosis and Prognosis of Age-Associated Bone Diseases. Biomolecules. 2020;10(4):589.
[16] HADJIARGYROU M, KOMATSU DE. The Therapeutic Potential of MicroRNAs as Orthobiologics for Skeletal Fractures. J Bone Miner Res. 2019;34:797-809.
[17] ZARECKI P, HACKL M, GRILLARI J, et al. Serum microRNAs as novel biomarkers for osteoporotic vertebral fractures. Bone. 2020;130: 115105.
[18] KANGAS R, TORMAKANGAS T, FEY V, et al. Aging and serum exomiR content in women-effects of estrogenic hormone replacement therapy. Sci Rep. 2017;7:42702.
[19] ZHANG J, YU X, YU Y, et al. MicroRNA expression analysis during FK506-induced osteogenic differentiation in rat bone marrow stromal cells. Mol Med Rep. 2017;16:581-590.
[20] YANG Y, FANG S. Small non-coding RNAs-based bone regulation and targeting therapeutic strategies. Mol Cell Endocrinol. 2017;456:16-35.
[21] FANG T, WU Q, ZHOU L, et al. miR-106b-5p and miR-17-5p suppress osteogenic differentiation by targeting Smad5 and inhibit bone formation. Exp Cell Res. 2016;347:74-82.
[22] HU H, HE X, ZHANG Y, et al. MicroRNA Alterations for Diagnosis, Prognosis, and Treatment of Osteoporosis: A Comprehensive Review and Computational Functional Survey. Front Genet. 2020;11:181.
[23] CHEN YJ, CHANG WA, HUANG MS, et al. Identification of novel genes in aging osteoblasts using next-generation sequencing and bioinformatics. Oncotarget. 2017;8:113598-113613.
[24] ZHENG CX, SUI BD, LIU N, et al. Adipose mesenchymal stem cells from osteoporotic donors preserve functionality and modulate systemic inflammatory microenvironment in osteoporotic cytotherapy. Sci Rep. 2018;8:5215.
[25] HE H, CHEN K, WANG F, et al. miR-204-5p promotes the adipogenic differentiation of human adipose-derived mesenchymal stem cells by modulating DVL3 expression and suppressing Wnt/beta-catenin signaling. Int J Mol Med. 2015;35:1587-1595.
[26] MEI Y, BIAN C, LI J, et al. miR-21 modulates the ERK-MAPK signaling pathway by regulating SPRY2 expression during human mesenchymal stem cell differentiation. J Cell Biochem. 2013;114:1374-1384.
[27] SHUAI Y, JIANG Z, YUAN Q, et al. Deciphering the Underlying Mechanism of Eucommiae Cortex against Osteoporotic Fracture by Network Pharmacology. Evid Based Complement Alternat Med. 2020;2020:7049812.
[28] ZHANG H, HU H, GREELEY N, et al. STAT3 restrains RANK- and TLR4-mediated signalling by suppressing expression of the E2 ubiquitin-conjugating enzyme Ubc13. Nat Commun. 2014;5:5798.
[29] SOWERWINE KJ, SHAW PA, GU W, et al. Bone density and fractures in autosomal dominant hyper IgE syndrome. J Clin Immunol. 2014;34: 260-264.
[30] NICOLAIDOU V, WONG MM, REDPATH AN, et al. Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation. PLoS One. 2012;7:e39871.
[31] BUETTMANN EG, MCKENZIE JA, MIGOTSKY N, et al. VEGFA From Early Osteoblast Lineage Cells (Osterix+) Is Required in Mice for Fracture Healing. J Bone Miner Res. 2019;34:1690-1706.
[32] TOMLINSON RE, MCKENZIE JA, SCHMIEDER AH, et al. Angiogenesis is required for stress fracture healing in rats. Bone. 2013;52:212-219.
[33] DUAN X, MURATA Y, LIU Y, et al. Vegfa regulates perichondrial vascularity and osteoblast differentiation in bone development. Development. 2015;142:1984-1991.
[34] HU K, OLSEN BR. Osteoblast-derived VEGF regulates osteoblast differentiation and bone formation during bone repair. J Clin Invest. 2016;126:509-526.
[35] GHAYOR C, WEBER FE. Epigenetic Regulation of Bone Remodeling and Its Impacts in Osteoporosis. Int J Mol Sci. 2016;17(9):1446.
[36] LAMOUREUX F, BAUD’HUIN M, RODRIGUEZ CALLEJA L, et al. Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. Nat Commun. 2014;5:3511.
[37] HIGUCHI C, MYOUI A, HASHIMOTO N, et al. Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J Bone Miner Res. 2002;17:1785-1794.
[38] SUN X, XIE Z, MA Y, et al. TGF-beta inhibits osteogenesis by upregulating the expression of ubiquitin ligase SMURF1 via MAPK-ERK signaling. J Cell Physiol. 2018;233:596-606.
[39] MACFARLANE EG, HAUPT J, DIETZ HC, et al. TGF-beta Family Signaling in Connective Tissue and Skeletal Diseases. Cold Spring Harb Perspect Biol. 2017;9(11):a022269.
[40] HAGHIGHIZADEH E, SHAHREZAEE M, SHARIFZADEH SR, et al. Transforming growth factor-beta3 relation with osteoporosis and osteoporotic fractures. J Res Med Sci. 2019;24:46.
[41] SUN X, LI X, QI H, et al. MiR-21 nanocapsules promote early bone repair of osteoporotic fractures by stimulating the osteogenic differentiation of bone marrow mesenchymal stem cells. J Orthop Translat. 2020;24: 76-87.
[42] LI H, LI T, FAN J, et al. miR-216a rescues dexamethasone suppression of osteogenesis, promotes osteoblast differentiation and enhances bone formation, by regulating c-Cbl-mediated PI3K/AKT pathway. Cell Death Differ. 2015;22:1935-1945.
[43] DE-UGARTE L, YOSKOVITZ G, BALCELLS S, et al. MiRNA profiling of whole trabecular bone: identification of osteoporosis-related changes in MiRNAs in human hip bones. BMC Med Genomics. 2015;8:75. |